These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 9592778)

  • 41. [Continuous arteriovenous hemofiltration in the newborn surgical patient].
    Rodríguez Vargas J; Arroyo Carrera I; Carretero Díaz V
    Cir Pediatr; 1991 Oct; 4(4):206-8. PubMed ID: 1760264
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of continuous renal replacement therapy on drug therapy.
    Susla GM
    Clin Pharmacol Ther; 2009 Nov; 86(5):562-5. PubMed ID: 19727069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relevance of platelet-activating factor in inflammation and sepsis: mechanisms and kinetics of removal in extracorporeal treatments.
    Tetta C; Mariano F; Buades J; Ronco C; Wratten ML; Camussi G
    Am J Kidney Dis; 1997 Nov; 30(5 Suppl 4):S57-65. PubMed ID: 9372980
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Septicaemia and the prevention of multiorgan failure--the intensive care perspective.
    Crowley K; Phelan D
    Ir Med J; 1990 Sep; 83(3):121-4. PubMed ID: 2228536
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Use of continuous veno-venous high volume hemofiltration (CVVHVH) in patients with multiple organ failure. Principle and applications].
    Lange R; Erhard J; Sander A; Scherer R; Eigler F
    Zentralbl Chir; 1996; 121(7):535-40; discussion 541-4. PubMed ID: 8967192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytokine removal in septic patients with continuous venovenous hemofiltration.
    Heering P; Grabensee B; Brause M
    Kidney Blood Press Res; 2003; 26(2):128-34. PubMed ID: 12771539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis.
    Ronco C; Tetta C; Mariano F; Wratten ML; Bonello M; Bordoni V; Cardona X; Inguaggiato P; Pilotto L; d'Intini V; Bellomo R
    Artif Organs; 2003 Sep; 27(9):792-801. PubMed ID: 12940901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From Continuous Renal Replacement Therapies to Multiple Organ Support Therapy.
    Ricci Z; Romagnoli S; Ronco C; La Manna G
    Contrib Nephrol; 2018; 194():155-169. PubMed ID: 29597227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Continuous blood purification therapy in 22 children with sepsis].
    Lu GP; Lu ZJ; Zhang LE; He J; Hu J; Wu F
    Zhonghua Er Ke Za Zhi; 2006 Aug; 44(8):573-8. PubMed ID: 17083779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Continuous dialysis and hemofiltration. More than a kidney replacement method?].
    Girndt M; Köhler H
    Anaesthesist; 2003 Dec; 52 Suppl 1():S40-4. PubMed ID: 14727050
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of continuous venovenous hemofiltration on pulmonary function and hemodynamics in postoperative septic multiorgan failure.
    Krüger I; Jacobi C; Landwehr P
    Contrib Nephrol; 1995; 116():108-11. PubMed ID: 8529361
    [No Abstract]   [Full Text] [Related]  

  • 52. [Hemofiltration and its changes in multiple organ failure].
    Vatazin AV
    Anesteziol Reanimatol; 1995; (3):55-9. PubMed ID: 7653869
    [No Abstract]   [Full Text] [Related]  

  • 53. Blood and plasma treatments: the rationale of high-volume hemofiltration.
    Honoré PM; Joannes-Boyau O; Gressens B
    Contrib Nephrol; 2007; 156():387-95. PubMed ID: 17464149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hemofiltration in multiorgan failure syndrome secondary to sepsis: a critical analysis of heterogeneity.
    Gotloib L
    Nephron; 1996; 73(2):125-30. PubMed ID: 8773332
    [No Abstract]   [Full Text] [Related]  

  • 55. [Critical care for organ failure].
    Shiga H; Hirasawa H
    Nihon Geka Gakkai Zasshi; 1998 Aug; 99(8):528-32. PubMed ID: 9789289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Year in review 2007: Critical Care--multiple organ failure and sepsis.
    O'Brien JM; Ali NA; Abraham E
    Crit Care; 2008; 12(5):228. PubMed ID: 18983708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Several aspects of optimization of hemofiltration in patients with peritonitis during the multiorgan failure stage].
    Ender LA; Vatazin AV; Fomin AM; Machulina NIu
    Anesteziol Reanimatol; 1993; (3):43-6. PubMed ID: 7943904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extracorporeal blood purification therapy for sepsis and systemic inflammation: its biological rationale.
    Bellomo R; Baldwin I; Ronco C
    Contrib Nephrol; 2001; (132):367-74. PubMed ID: 11395904
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Sepsis. II. Complications and treatment of sepsis].
    Makovický P; Mokán M; Vladár L; Vrlík M
    Cas Lek Cesk; 1996 Oct; 135(19):614-6. PubMed ID: 8998803
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-renal indications for continuous renal replacement therapy.
    Schetz M
    Kidney Int Suppl; 1999 Nov; (72):S88-94. PubMed ID: 10560814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.